Biotechnology Companies Reaching New Milestones

Sep 22, 2016, 09:00 ET from

NEW YORK, September 22, 2016 /PRNewswire/ --

Transparency Market Research published a report on the global biotechnology market and claiming that this vibrant market is expected to grow at an average annual growth rate of CAGR rate of 11.6% by the end of 2017. The data provided indicates that in 2011, the market was valued at roughly $216.5 billion, yet major changes in the way the industry operates and innovative developments in the sector, have pushed values to reach $414.5 billion by the end of 2017. Allergan PLC (NYSE: AGN), Tobira Therapeutics, Inc. (NASDAQ: TBRA), MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Puma Biotechnology Inc. (NYSE: PBYI).

This week, Allergan PLC (NYSE: AGN) announced the acquisition of biopharmaceutical company, Tobira Therapeutics, Inc. (NASDAQ: TBRA) in a deal worth as much as $1.7 billion, a move to gain more exposure in the liver diseases therapies area. Allergan has agreed to make a direct payment of $28.35 a share in cash and as much as $49.84 a share based on the successful completion of certain developments, regulatory and commercial milestones. Even if the company does not reach certain developments, the offer still represents a 498 percent premium to Tobira's closing price of $4.74 a share earlier in the week. Shares of Tobira skyrocketed over 700 percent after the announcement.

Another small cap company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), has released the current progress of its antibody development program, HuMab-5B1. MabVax worked on two clinical trials this year with therapeutic agent (MVT-5873), a new generation PET imaging product (MVT-2163), and a radio immunotherapy agent (MVT-1075), and plans on filing an Investigational New Drug with the U.S. Food and Drug Administration later this year. On August 17th, MabVax Therapeutics reached a corporate milestone by successfully completing their uplisting and started to trade on NASDAQ exchange.

MabVax Therapeutics Holdings, Inc. (MBVX) Phase I trial for MVT-5873 began in the first quarter of this year to evaluate the safety, tolerability and pharmacokinetics as a single agent or in combination with a standard of care chemotherapy. The trial is currently examining patients with metastatic pancreatic cancer. The MVT-2163 is a positron emission tomography PET imaging agent. The Phase I trial began in the second quarter of this year. In preclinical models the use of the imaging agent resulted in high-resolution images of tumors in xenograft animal models, and now being tested on humans in hopes to help with diagnosis, monitoring, and assessment of patients with pancreatic cancer. MabVax's collaborations with key cancer research centers and oncology companies include the Memorial Sloan Kettering Cancer Center, Rockefeller University and Heidelberg Pharma.

Pharmaceutical company, Aerie Pharmaceuticals Inc. (NASDAQ: AERI) continues to rally after many Wall Street investment research firms upgraded the company to a "buy". Aerie has disclosed effective phase 3 trial results for its glaucoma drug, Roclatan. Roclatan is capable of reducing intraocular pressure (IOP) in patients who has glaucoma or ocular hypertension. Aerie is a clinical-stage pharmaceutical company mainly focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with diseases of the eye. Ever since the release of the reports, shares soared over 50 percent and peaked all-time highs at $38.74.

Shares of Puma Biotechnology Inc. (NYSE: PBYI) surged over 13.5 percent after the U.S. Food and Drug Administration accepted its New Drug Application to treat breast cancer, the PB272 (Neratinib). Neratinib allows the company to treat extended adjuvant patients with early stage HER2-overexpressed breast cancer who have also had prior adjuvant breast cancer therapy with Herceptin (trastuzumab). Puma Biotechnology is a biopharmaceutical company devoted to the acquisition and development of novel therapeutics for the treatment of cancer.

For "The Latest Buzz in Financial News", SIGN UP & Visit:

Follow us on Twitter for real time Financial News Updates:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. has been compensated twelve thousand dollars for financial news pr services by a non-affiliated third party. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting the high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof.  The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print.  Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use.

Please visit:

For further information:

Media Contact: Danny Abramov,, +1-877-601-1879